Literature DB >> 34096630

Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.

Jason Ostergaard1,2, Leslie M Jonart1,2, Maryam Ebadi1,2, Stacia L Koppenhafer3, David J Gordon3, Peter M Gordon1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34096630      PMCID： PMC8504167          DOI： 10.1111/bjh.17610

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  15 in total

1.  Drug combination studies and their synergy quantification using the Chou-Talalay method.

Authors:  Ting-Chao Chou
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

2.  Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.

Authors:  Rishi S Kotecha; Ronald W Stam; Priscilla Wander; Laurence C Cheung; Sandra S Pinhanҫos; Luke Jones; Mark Kerstjens; Susan T C J M Arentsen-Peters; Sajla Singh; Grace-Alyssa Chua; Patricia Garrido Castro; Pauline Schneider; M Emmy M Dolman; Bianca Koopmans; Jan J Molenaar; Rob Pieters; C Michel Zwaan
Journal:  Leukemia       Date:  2020-06-02       Impact factor: 11.528

3.  CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.

Authors:  L M Sarmento; V Póvoa; R Nascimento; G Real; I Antunes; L R Martins; C Moita; P M Alves; M Abecasis; L F Moita; R M E Parkhouse; J P P Meijerink; J T Barata
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

Review 4.  Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.

Authors:  Gesuino Angius; Silverio Tomao; Valeria Stati; Patrizia Vici; Vincenzo Bianco; Federica Tomao
Journal:  Cancer Chemother Pharmacol       Date:  2019-09-11       Impact factor: 3.333

5.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

6.  LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Authors:  Darlene Barnard; H Bruce Diaz; Teresa Burke; Gregory Donoho; Richard Beckmann; Bonita Jones; David Barda; Constance King; Mark Marshall
Journal:  Invest New Drugs       Date:  2015-11-27       Impact factor: 3.850

7.  St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem.

Authors:  Clay McLeod; Alexander M Gout; Xin Zhou; Andrew Thrasher; Delaram Rahbarinia; Samuel W Brady; Michael Macias; Kirby Birch; David Finkelstein; Jobin Sunny; Rahul Mudunuri; Brent A Orr; Madison Treadway; Bob Davidson; Tracy K Ard; Arthur Chiao; Andrew Swistak; Stephanie Wiggins; Scott Foy; Jian Wang; Edgar Sioson; Shuoguo Wang; J Robert Michael; Yu Liu; Xiaotu Ma; Aman Patel; Michael N Edmonson; Mark R Wilkinson; Andrew M Frantz; Ti-Cheng Chang; Liqing Tian; Shaohua Lei; S M Ashiqul Islam; Christopher Meyer; Naina Thangaraj; Pamella Tater; Vijay Kandali; Singer Ma; Tuan Nguyen; Omar Serang; Irina McGuire; Nedra Robison; Darrell Gentry; Xing Tang; Lance E Palmer; Gang Wu; Ed Suh; Leigh Tanner; James McMurry; Matthew Lear; Alberto S Pappo; Zhaoming Wang; Carmen L Wilson; Yong Cheng; Soheil Meshinchi; Ludmil B Alexandrov; Mitchell J Weiss; Gregory T Armstrong; Leslie L Robison; Yutaka Yasui; Kim E Nichols; David W Ellison; Chaitanya Bangur; Charles G Mullighan; Suzanne J Baker; Michael A Dyer; Geralyn Miller; Scott Newman; Michael Rusch; Richard Daly; Keith Perry; James R Downing; Jinghui Zhang
Journal:  Cancer Discov       Date:  2021-01-06       Impact factor: 39.397

8.  Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.

Authors:  Andrea Ghelli Luserna Di Rorà; Ilaria Iacobucci; Enrica Imbrogno; Cristina Papayannidis; Enrico Derenzini; Anna Ferrari; Viviana Guadagnuolo; Valentina Robustelli; Sarah Parisi; Chiara Sartor; Maria Chiara Abbenante; Stefania Paolini; Giovanni Martinelli
Journal:  Oncotarget       Date:  2016-08-16

9.  SynergyFinder 2.0: visual analytics of multi-drug combination synergies.

Authors:  Aleksandr Ianevski; Anil K Giri; Tero Aittokallio
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

10.  Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.

Authors:  Bhagwan Yadav; Krister Wennerberg; Tero Aittokallio; Jing Tang
Journal:  Comput Struct Biotechnol J       Date:  2015-09-25       Impact factor: 7.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.